September 29, 2026
AstraZeneca to invest $2bn in Summit for ADC combination therapies
AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and antibody-drug conjugates (ADCs) across multiple tumour types.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







